Clinicopathologic Changes in Children with Immunoglobulin A Nephritis and Henoch-Schönlein Purpura Nephritis after Cyclosporine A and Angiotensin-converting Enzyme Inhibitor Treatment
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate the clinicopathologic effects of cyclosporine A (CsA) in children with diseases characterized by mesangial immunoglobulin A deposits such as immunoglobulin A nephropathy (IgAN) and Henoch-Schönlein purpura nephritis (HSPN). Methods: We retrospectively reviewed the clinicopathologic outcomes of 54children (IgAN, 36; HSPN, 18) treated with CsA. The starting dose of CsA was 5mg/kg per day, and it was administered in 2 divided doses. The degree of proteinuria and pathologic changes in renal biopsies were evaluated before and after CsA treatment. Results: The mean protein to creatinine ratio decreased from 3.7±1.5 to 0.6±0.4(P <0.001), and 32 (59.2%) children achieved complete remission of proteinuria after 1-year CsA treatment. Among the 54 children, 24 maintained normal renal function and 25 exhibited microscopic hematuria or proteinuria at the end of CsA treatment. In the HSPN group, 3 children whose initial biopsies indicated class IIIb disease showed class II disease on follow-up, and the follow-up biopsies of 2children who had class II disease indicated the same class II disease. In the IgAN group, cortical tubular atrophy occurred in 1 child, and no child with IgAN had cortical interstitial fibrosis or tubular atrophy after 1-year CsA treatment. No significant complications were found in the children treated with CsA. Conclusion: Our findings indicate that CsA treatment is effective and beneficial in reducing massive proteinuria and preventing progression to end-stage renal failure in children with glomerular diseases characterized by IgA deposits, such as IgAN and HSPN, within 1 year of treatment.
Abstract
Purpose: To investigate the clinicopathologic effects of cyclosporine A (CsA) in children with diseases characterized by mesangial immunoglobulin A deposits such as immunoglobulin A nephropathy (IgAN) and Henoch-Schönlein purpura nephritis (HSPN). Methods: We retrospectively reviewed the clinicopathologic outcomes of 54children (IgAN, 36; HSPN, 18) treated with CsA. The starting dose of CsA was 5mg/kg per day, and it was administered in 2 divided doses. The degree of proteinuria and pathologic changes in renal biopsies were evaluated before and after CsA treatment. Results: The mean protein to creatinine ratio decreased from 3.7±1.5 to 0.6±0.4(P <0.001), and 32 (59.2%) children achieved complete remission of proteinuria after 1-year CsA treatment. Among the 54 children, 24 maintained normal renal function and 25 exhibited microscopic hematuria or proteinuria at the end of CsA treatment. In the HSPN group, 3 children whose initial biopsies indicated class IIIb disease showed class II disease on follow-up, and the follow-up biopsies of 2children who had class II disease indicated the same class II disease. In the IgAN group, cortical tubular atrophy occurred in 1 child, and no child with IgAN had cortical interstitial fibrosis or tubular atrophy after 1-year CsA treatment. No significant complications were found in the children treated with CsA. Conclusion: Our findings indicate that CsA treatment is effective and beneficial in reducing massive proteinuria and preventing progression to end-stage renal failure in children with glomerular diseases characterized by IgA deposits, such as IgAN and HSPN, within 1 year of treatment.
참고문헌 (36)
- Donadio JV, "IgA nephropathy", N Engl J Med, 347, pp.738~748 (2002)
- D'Amico G, "Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors", Am J Kidney Dis, 36, pp.227~237 (2000)
- Katafuchi R, "Microvascular disease and the progression of IgA nephropathy", Am J Kidney Dis, 15, pp.72~79 (1990)
- Ozen S, "EULAR", PReS endorsed consensus criteria for the classification of childhood vasculitides, 2006, pp.65, 936~941
- Koutkia P, "Leucocytoclastic vasculitis: an update for the clinician", Scand J Rheumatol, 30, pp.315~322 (2001)
- Davin JC, "Henoch-Schönlein purpura nephritis: an update", Eur J Pediatr, 160, pp.689~695 (2001)
- Lee TH, "Concurrent occurrence of chylothorax and chylous ascites in a patient with Henoch-Schönlein purpura", Scand J Rheumatol, 32, pp.378~379 (2003)
- Kaku Y, "Renal involvement in Henoch- Schönlein purpura: a multivariate analysis of prognostic factors", Kidney Int, 53, pp.1755~1759 (1998)
- Ronkainen J, "Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria", Clin Nephrol, 60, pp.80~84 (2003)
- Counahan R, "Prognosis of Henoch-Schönlein nephritis in children", Br Med J, 2, pp.11~14 (1977)
- Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, "The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification", Kidney Int, 76, pp.534~545 (2009)
- Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, "The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility", Kidney Int, 76, pp.546~556 (2009)
- 신재일, "Effects of Cyclosporin A Therapy Combined with Steroids and Angiotensin Converting Enzyme Inhibitors on Childhood IgA Nephropathy", Journal of Korean Medical Science, 25(5), pp.723~727 (2010), 대한의학회
- Park JM, "Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria", Pediatr Nephrol, 26, pp.411~417 (2011)
- Shin JI, "Henoch- Schönlein purpura nephritis with nephrotic-range proteinuria: histological regression possibly associated with cyclosporin A and steroid treatment", Scand J Rheumatol, 34, pp.392~395 (2005)
- Egido J, "A possible common pathogenesis of the mesangial IgA glomerulonephritis in patients withBerger's disease and Schonlein-Henoch syndrome", Proc Eur Dial Transplant Assoc, 17, pp.660~666 (1980)
- Waldo FB, "Is Henoch-Schonlein purpura the systemic form of IgA nephropathy?", Am J Kidney Dis, 12, pp.373~377 (1988)
- Levy M, "Familial cases of Berger's disease and anaphylactoid purpura: more frequent than previously thought", Am J Med, 87, pp.246~248 (1989)
- Montoliu J, "Henoch-Schonlein purpura and IgA nephropathy in father and son", Nephron, 54, pp.77~79 (1990)
- Thorner PS, "IgA nephropathy: Henoch-Schonlein purpura and Berger's disease in one patient", Int J Pediatr Nephrol, 7, pp.131~136 (1986)
- Chishiki M, "A 10-year-old girl with IgA nephropathy who 5 years later developed the characteristic features of Henoch-Schonlein purpura nephritis", Fukushima J Med Sci, 56, pp.157~161 (2010)
- Meadow SR, "Berger disease: Henoch-Schonlein syndrome without the rash", J Pediatr, 106, pp.27~32 (1985)
- Rai A, "Henoch-Schonlein purpura nephritis", J Am Soc Nephrol, 10, pp.2637~2644 (1999)
- D'Amico G, "Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome", Semin Nephrol, 24, pp.179~196 (2004)
- Jardim HM, "Crescentic glomerulonephritis in children", Pediatr Nephrol, 6, pp.231~235 (1992)
- Niaudet P, "Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis", Pediatr Nephrol, 12, pp.238~243 (1998)
- Shin JI, "Can azathioprine and steroids alter the progression of severe Henoch-Schönlein nephritis in children?", Pediatr Nephrol, 20, pp.1087~1092 (2005)
- Yoshikawa N, "A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group", J Am Soc Nephrol, 10, pp.101~109 (1999)
- Lai KN, "A short-term controlled trial of cyclosporine A in IgA nephropathy", Transplant Proc, 20(4), pp.297~303 (1988)
- Borel JF, "Pharmacology of cyclosporine (sandimmune). IV. Pharmacological properties in vivo", Pharmacol Rev, 41, pp.259~371 (1990)
- Wiegmann TB, "In vitro effects of cyclosporine on glomerular function", Am J Med Sci, 299, pp.149~152 (1990)
- Faul C, "The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A", Nat Med, 14, pp.931~938 (2008)
- Seikaly MG, "Long-term clinical and pathological effects of cyclosporin in children with nephrosis", Pediatr Nephrol, 14, pp.214~217 (2000)
- Iijima K, "Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephritic syndrome", Kidney Int, 61, pp.1801~1805 (2002)
- Kengne-Wafo S, "Idiopathic membranous nephropathy associated with polycystic kidney disease", Pediatr Nephrol, 25, pp.961~963 (2010)
- Hausberg M, "ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients", Hypertension, 33, pp.862~868 (1999)